Meta-analysis of clinical trials of ivermectin to treat COVID-19 infection
, A., Preprint (Preprint) (meta analysis)
WHO-funded meta analysis showing ivermectin treatment mortality relative risk RR 0.17 [0.08-0.35] for RCTs and RR 0.28 [0.13-0.62] for RCTs and observational studies, and confirming a dose-response effect.Currently there are
82 ivermectin
for COVID-19 studies, showing 53% [39‑64%] lower mortality, 31% [11‑46%] lower ventilation, 54% [36‑67%] lower ICU admission, 38% [24‑49%] lower hospitalization, and 78% [67‑86%] lower cases.
Hill et al., 12/27/2020, preprint, 1 author.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.